Transgene SA (TNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transgene SA (TNG) has a cash flow conversion efficiency ratio of -0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.55 Million ≈ $-21.69 Million USD) by net assets (€121.73 Million ≈ $142.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Transgene SA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Transgene SA - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vertical Aerospace Ltd
NYSE:EVTL
|
0.276x |
|
Exotic Food Public Company Limited
BK:XO
|
0.107x |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
0.044x |
|
Azkoyen
MC:AZK
|
0.141x |
|
Daewonkangup
KO:000430
|
0.039x |
|
Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
NASDAQ:AXIN
|
-0.001x |
|
Nam Kim Steel JSC
VN:NKG
|
0.104x |
|
Icelandic Salmon As
OL:ISLAX
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2025)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Transgene SA (TNG) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €121.73 Million ≈ $142.32 Million |
€-36.74 Million ≈ $-42.95 Million |
-0.302x | +80.52% |
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
€-23.55 Million ≈ $-27.53 Million |
-1.549x | +30.26% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
€-34.67 Million ≈ $-40.53 Million |
-2.221x | -313.91% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
€-20.30 Million ≈ $-23.74 Million |
-0.537x | -12.89% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
€-31.94 Million ≈ $-37.34 Million |
-0.475x | +16.91% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
€-28.74 Million ≈ $-33.60 Million |
-0.572x | -67.66% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
€-22.41 Million ≈ $-26.20 Million |
-0.341x | +55.88% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-0.773x | +38.59% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
€-35.37 Million ≈ $-41.35 Million |
-1.259x | -74.35% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
€-33.59 Million ≈ $-39.26 Million |
-0.722x | +57.54% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
€-45.15 Million ≈ $-52.79 Million |
-1.701x | -125.29% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
€-54.24 Million ≈ $-63.41 Million |
-0.755x | +14.82% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
€-50.19 Million ≈ $-58.67 Million |
-0.886x | -72.06% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
€-51.29 Million ≈ $-59.97 Million |
-0.515x | -64.95% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
€-44.16 Million ≈ $-51.63 Million |
-0.312x | -130.02% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
€-24.93 Million ≈ $-29.14 Million |
-0.136x | +50.28% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
€-18.72 Million ≈ $-21.89 Million |
-0.273x | -10.00% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
€-23.39 Million ≈ $-27.34 Million |
-0.248x | -1228.28% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
€-2.07 Million ≈ $-2.42 Million |
-0.019x | +98.18% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
€-19.54 Million ≈ $-22.84 Million |
-1.029x | +23.32% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
€-19.11 Million ≈ $-22.34 Million |
-1.343x | -154.45% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
€-18.21 Million ≈ $-21.29 Million |
-0.528x | -81.78% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
€-16.02 Million ≈ $-18.73 Million |
-0.290x | -35.93% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
€-15.72 Million ≈ $-18.38 Million |
-0.214x | +66.64% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
€-22.27 Million ≈ $-26.03 Million |
-0.640x | -155.78% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
€-13.88 Million ≈ $-16.23 Million |
-0.250x | +45.04% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
€-33.47 Million ≈ $-39.13 Million |
-0.455x | +19.95% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
€-11.77 Million ≈ $-13.76 Million |
-0.569x | -- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more